Evidence map›Paper›PMID 28479526›Full record

Trial reportWorld neurosurgery2017

Superion Interspinous Spacer Treatment of Moderate Spinal Stenosis: 4-Year Results.

Pierce D Nunley, Vikas V Patel, Douglas G Orndorff, William F Lavelle, Jon E Block, Fred H Geisler

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World neurosurgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Editorial on: "SuperionJournal of spine surgery (Hong Kong) · 2018
    Article
  17. Article
  18. Article
  19. Idio Scale Judgment: evaluation of a new method for estimating responder thresholds.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Pierce D NunleySpine Institute of Louisiana, Shreveport, Louisiana, USA.
Vikas V PatelThe Spine Center, University of Colorado Hospital, Denver, Colorado, USA.
Douglas G OrndorffSpine Colorado, Mercy Regional Hospital, Durango, Colorado, USA.
William F LavelleUpstate Bone and Joint Center, East Syracuse, New York, USA.
Jon E BlockPrivate practice, San Francisco, California, USA. Electronic address: jb@drjonblock.com.
Fred H GeislerPrivate practice, Chicago, Illinois, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine 4-year clinical outcomes in patients with moderate lumbar spinal stenosis treated with minimally invasive stand-alone interspinous process decompression using the Superion device.

methodsThe 4-year Superion data were extracted from a randomized, controlled Food and Drug Administration investigational device exemption trial. Patients with intermittent neurogenic claudication relieved with back flexion who failed at least 6 months of nonsurgical management were enrolled. Outcomes included Zurich Claudication Questionnaire (ZCQ) symptom severity (ss), physical function (pf) and patient satisfaction (ps) subdomains, leg and back pain visual analog scale (VAS), and Oswestry Disability Index (ODI). At 4-year follow-up, 89 of the 122 patients (73%) provided complete clinical outcome evaluations.

resultsAt 4 years after index procedure, 75 of 89 patients with Superion (84.3%) demonstrated clinical success on at least 2 of 3 ZCQ domains. Individual component responder rates were 83% (74/89), 79% (70/89), and 87% (77/89) for ZCQss, ZCQpf, and ZCQps; 78% (67/86) and 66% (57/86) for leg and back pain VAS; and 62% (55/89) for ODI. Patients with Superion also demonstrated percentage improvements over baseline of 41%, 40%, 73%, 69%, and 61% for ZCQss, ZCQpf, leg pain VAS, back pain VAS, and ODI. Within-group effect sizes all were classified as very large (>1.0): 1.49, 1.65, 1.42, 1.12, and 1.46 for ZCQss, ZCQpf, leg pain VAS, back pain VAS, and ODI.

conclusionsMinimally invasive implantation of the Superion device provides long-term, durable relief of symptoms of intermittent neurogenic claudication for patients with moderate lumbar spinal stenosis.

Indexed as

AdultAgedAged, 80 and overCausalityDecompression, SurgicalEquipment Failure AnalysisFemaleHumansLongitudinal StudiesMaleMiddle AgedPainPrevalenceProstheses and ImplantsProsthesis DesignRisk FactorsDecompressionInterspinous spacerLumbar spinal stenosisNeurogenic claudicationSuperion

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.